Data from Clinicaltrials.gov - Curated by EPG Health - Last updated 15 February 2017
purposeThis is a double-blind, placebo-controlled, event-driven randomized withdrawal study to investigate the efficacy and safety of secukinumab treatment in the Juvenile Idiopathic Arthritis (JIA) categories of Juvenile Psoriatic Arthritis (JPsA) and Enthesitis-related Arthritis (ERA). The study is divided into 3 parts (plus a post-treatment follow-up period) consisting of open-label, single-arm active treatment in Treatment Periods 1 and 3 and a randomized, double-blind, placebo controlled, event-driven withdrawal design in Treatment Period 2.
|Date last updated at source||07-Feb-17|
|Study start date||15-Mar-17|
|Estimated primary completion date||30-Dec-20|